Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA

References

• MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med2006311e44217132052
   PubMed Web of Science ®Google Scholar
• Diaz-GuzmanEManninoDMEpidemiology and prevalence of chronic obstructive pulmonary diseaseClin Chest Med201435171624507833
   PubMed Web of Science ®Google Scholar
• HoggJCTimensWThe pathology of chronic obstructive pulmonary diseaseAnnu Rev Pathol2009443545918954287
   PubMed Web of Science ®Google Scholar
• SalviSSBarnesPJChronic obstructive pulmonary disease in non-smokersLancet2009374969173374319716966
   PubMed Web of Science ®Google Scholar
• OharJSterlingDABleeckerEDonohueJChanging patterns in asbestos-induced lung diseaseChest2004125274475314769760
   PubMed Web of Science ®Google Scholar
• McDonoughJEYuanRSuzukiMSmall-airway obstruction and emphysema in chronic obstructive pulmonary diseaseN Engl J Med2011365171567157522029978
   PubMed Web of Science ®Google Scholar
• SeniorRAtkinsonJChronic obstructive pulmonary disease: epidemiology, pathophysiology, and pathogenesisAlfred FishmanMFishman’s Pulmonary Diseases and Disorders14th edNew York, NYMcGraw Hill Medical2008707728
   Google Scholar
• O’DonnellDELavenezianaPPhysiology and consequences of lung hyperinflation in COPDEur Respir Rev2006151006167
   Google Scholar
• CasanovaCCoteCde TorresJPInspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2005171659159715591470
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlugeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994
   PubMed Web of Science ®Google Scholar
• The Global Strategy for the Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)2015 Available from: http://www.goldcopd.orgAccessed March 8, 2015
   Google Scholar
• QaseemAWiltTJWeinbergerSEDiagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnn Intern Med2011155317919121810710
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575 Pt 1141814229603117
   PubMed Web of Science ®Google Scholar
• VestboJEdwardsLDScanlonPDChanges in forced expiratory volume in 1 second over time in COPDN Engl J Med2011365131184119221991892
   PubMed Web of Science ®Google Scholar
• SinganayagamASchembriSChalmersJDPredictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary diseaseAnn Am Thorac Soc2013102818923607835
   PubMedGoogle Scholar
• Soler-CatalunaJJMartinez-GarciaMARoman SanchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• MarchettiNCrinerGJAlbertRKPreventing acute exacerbations and hospital admissions in COPDChest201314351444145423648908
   PubMed Web of Science ®Google Scholar
• OharJASadeghnejadAMeyersDADonohueJFBleeckerERDo symptoms predict COPD in smokers?Chest201013761345135320363841
   PubMed Web of Science ®Google Scholar
• BuistASMcBurnieMAVollmerWMInternational variation in the prevalence of COPD (the BOLD Study): a population-based prevalence studyLancet2007370958974175017765523
   PubMed Web of Science ®Google Scholar
• VanfleterenLESpruitMAGroenenMClusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2013187772873523392440
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev201264345050422611179
   PubMed Web of Science ®Google Scholar
• JacksonM“Divine stramonium”: the rise and fall of smoking for asthmaMed Hist201054217119420357985
   PubMed Web of Science ®Google Scholar
• BrayGWThe treatment of asthmaBr Med J19351386311912120778795
   PubMedGoogle Scholar
• U.S. Food and Drug AdministrationDepartment of Health and Human Services Tudorza Pressair (aclidinium bromide inhalation powder) approval letter2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/202450Orig1s000ltr.pdfAccessed November 22, 2014
   Google Scholar
• U.S. Food and Drug AdministrationDepartment of Health and Human Services Incruse Ellipta (umeclidinium bromide inhalation powder) approval letter2014 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205382Orig1s000ltr.pdfAccessed November 22, 2014
   Google Scholar
• MilesMCDonohueJFOharJACombination therapy for COPD: emerging evidence from recent clinical trialsJ Clin Invest201116879890
   Google Scholar
• CazzolaMMacNeeWMartinezFJOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J200831241646918238951
   PubMed Web of Science ®Google Scholar
• JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med2014189325025524383418
   PubMed Web of Science ®Google Scholar
• LeidyNKSextonCCJonesPWMeasuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diaryThorax201469544344924595666
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
   PubMed Web of Science ®Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther201023425726720381630
   PubMed Web of Science ®Google Scholar
• COMBIVENT Inhalation Aerosol Study GroupIn chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study GroupChest19941055141114198181328
   PubMed Web of Science ®Google Scholar
• CIAS GroupRoutine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study GroupChest19971126151415219404747
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensECombining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptomsRespir Med20101047995100420303247
   PubMed Web of Science ®Google Scholar
• DonohueJFAnzuetoABrooksJMehtaRKalbergCCraterGA randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPDRespir Med2012106797097922498110
   PubMed Web of Science ®Google Scholar
• HananiaNAFeldmanGZachgoWThe efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trialChest2012142111912722241764
   PubMed Web of Science ®Google Scholar
• Anoro™ [prescribing information]Durham, NCGlaxoSmithKline plc2013 Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-MG.PDFAccessed May 10, 2015
   Google Scholar
• MahlerDAKerwinEAyersTFLIGHT: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with COPDAm J Respir Crit Care Med Epub7152015
   Web of Science ®Google Scholar
• FeldmanGWalkerRRBrooksJMehtaRCraterG28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trialPulm Pharmacol Ther201225646547122955035
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• SinDDWanted: new treatments for COPDLancet Respir Med20142643443624835834
   PubMed Web of Science ®Google Scholar
• DonohueJFNiewoehnerDBrooksJO’DellDChurchASafety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyRespir Res20141517825015176
   PubMed Web of Science ®Google Scholar
• CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 μg therapy in COPD: a randomized, controlled studyChest2014145598199124385182
   PubMed Web of Science ®Google Scholar
• CHMP – Committee for Medicinal Products for Human UseInitial authorisation of Ultibro Breezhaler (indacaterol/glycopyrronium bromide)2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002679/WC500146589.pdfAccessed August 12, 2014
   Google Scholar
• NovartisNovartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDA2015 Available from: https://www.novartis.com/news/media-releases/novartis-announces-robust-phase-iii-results-qva149-and-nva237-and-submitsAccessed January 29, 2015
   Google Scholar
• European Medicines AgencySummary of positive opinion for Onbrez Breezhaler (indacaterol maleate)2009 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/001114/WC500059632.pdfAccessed August 12, 2014
   Google Scholar
• FDAIndacaterol FDA approval information Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetailsAccessed August 12, 2014
   Google Scholar
• European Medicines AgencyInitial authorisation Seebri Breezhaler (glycopyrronium bromide)2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002430/WC500129033.pdfAccessed August 12, 2014
   Google Scholar
• DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med2013107101558156723867808
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study (Supplementary Material)2013 Available from: http://www.erj.ersjournals.com/content/suppl/2013/09/03/09031936.00200212.DC1/erj02002-2012_online_supplementary_material.pdfAccessed August 12, 2014
   Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• AscheCVLeaderSPlauschinatCAdherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroidsInt J Chron Obstruct Pulmon Dis2012720120922500120
   PubMed Web of Science ®Google Scholar
• BourbeauJSebaldtRJDayAPractice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE studyCan Respir J2008151131918292848
   PubMed Web of Science ®Google Scholar
• WhitePThorntonHPinnockHGeorgopoulouSBoothHPOver-treatment of COPD with inhaled corticosteroids-implications for safety and costs: cross-sectional observational studyPLoS One2013810e7522124194824
   PubMed Web of Science ®Google Scholar
• KornSGebnerCSchurmannWOnce daily QVA149 improves dyspnea, quality of life and reduces the rate of exacerbations compared to tiotropium plus formoterol in COPD patients: the quantify studyAm J Respir Crit Care Med2014189A5982
   Web of Science ®Google Scholar
• GebnerCSchurmannWForsterKOnce daily QVA149 demonstrates superior improvements in lung function compared to tiotropium plus formoterol: the quantify studyAm J Respir Crit Care Med2014189A5983
   Web of Science ®Google Scholar
• MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyEur Respir J20144361599160924176997
   PubMed Web of Science ®Google Scholar
• D’UrzoAMergelVLeselbaumACaractaCEfficacy and safety of fixed-dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trialChest20131444_MeetingAbstracts1025A
   Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• RennardSD’UrzoAJonesPMergelVLeselbaumACaractaCFixed-dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trialAm J Respir Crit Care Med2014189A6007
   Web of Science ®Google Scholar
• DonohueJFD’UrzoASinghDCardiovascular safety of fixed-dose combination aclidinium bromide/formoterol fumarate: results of two 6-month studies in patients with moderate to severe COPDAm J Respir Crit Care Med2014189A6011
   Web of Science ®Google Scholar
• U.S. Food and Drug AdministrationDepartment of Health and Human ServicesStiolto Respimat (tiotropium bromide and olodaterol inhalation spray) approval letter2015 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/206756Orig1s000ltr.pdfAccessed July 30, 2015
   Google Scholar
• DeromEWestermanJGrönkeLHamiltonALiCBeehKP258 the 24-hour lung function profile of once-daily tiotropium and olodaterol fixed-dose combination compared with placebo and monotherapies in chronic obstructive pulmonary diseaseThorax201469Suppl 2A190A191
   Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• ReisnerCSt RoseEStromSFixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPDEur Respir J201138Suppl 55879
   Google Scholar
• JonesPWSinghDBatemanEDEfficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyEur Respir J201240483083622441743
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• BatemanERennardSJonesPMolinsEJinMLeselbaumAEffect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: pooled analysis of two studiesEur Respir J201444Suppl 58285
   Google Scholar
• JonesPWLamarcaRChuecosFCharacterisation and impact of reported and unreported exacerbations: results from ATTAINEur Respir J20144451156116525234803
   PubMed Web of Science ®Google Scholar
• IMS Health MIDASTop 20 global products2013 Available from: http://www.imshealth.com/cds/imshealth/Global/Content/Corporate/Press%20Room/Global_2013/Top_20_Global_Products_2013.pdfAccessed January 1, 2014
   Google Scholar
• SmallMBroomfieldSHigginsVQuantification and treatment patterns of Real-World Patients Classified by the GOLD 2011 StrategyThorax201267Suppl 2A144A145
   Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• BuhlRDeromEFergusonGOnce-daily tiotropium and olodaterol fixed-dose combination via the Respimat® improves outcomes vs mono-components in COPD in two 1-year studies.)Eur Respir J201444Suppl 58, OP1895
   Google Scholar
• BourbeauJBartlettSJPatient adherence in COPDThorax200863983183818728206
   PubMed Web of Science ®Google Scholar
• Garcia-AymerichJBarreiroEFarreroEMarradesRMMoreraJAntoJMPatients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study)Eur Respir J20001661037104211292102
   PubMed Web of Science ®Google Scholar